Zoomed Image
  • Daboral 125/5ml Syrup 60ml

Daboral 125/5ml Syrup 60ml

Daboral® contains Aminosidine Sulphate (paromomycin) which is an aminoglycoside antibiotic. Aminosidine has a broad spectrum of activity, including activity against protozoa especially Entamoeba histolytica, bacteria and cestodes. The drug is believed to act against both the trophozoite and encysted forms of Entamoeba. Aminosidine has an antibacterial spectrum similar to that of neomycin. Aminosidine is active against some gram-positive bacteria (e.g. some strains of Staphylococcus) and many gram-negative aerobic bacteria, but generally is inactive against Pseudomonas aeruginosa and anaerobic bacteria. Aminosidine also has some activity against Mycobacterium tuberculosis. Aminosidine has been shown to be active against certain cestodes (tapeworms) pathogenic to humans including Diphyllobothrium latum (fish tapeworm), Taenia saginata (beef tapeworm), and T.solium (pork tapeworm). Daboral® is used in the treatment of intestinal protozoal infections, including amoebiasis, cryptosporidiosis, and giardiasis. It has been used in the treatment of tapeworm infection. Also in the suppression of intestinal flora both pre-operatively and in the management of hepatic encephalopathy.
How to use
Amoebiasis, Giardiasis (Lambliasis) and Balantidiasis: Adults: 500 mg twice a day for 5-7 days. Children: 30 mg/kg/day in two divided doses for 5-7 days.
Cryptosporidiosis: Adults: 500mg four times a day for 14 days.
Gastro-enteritis and enterocolitis due to mixed flora, salmonellosis and shigellosis: Adults: 500 mg twice a day for 5-7 days. Children: 30 mg/kg/day in two divided doses for 5-7 days.
Prophylactic sterilization in gastro-intestinal surgery: Adults: 2 g daily for 3 days. Children: 50 mg/kg/day for 3 days.
Precautions: The use of Aminosidine may result in the overgrowth of non-susceptible organisms, especially Candida, and patients should be carefully monitored for the development of new infections caused by nonsusceptible organisms. Secondary Staphylococcus enterocolitis may occur. Aminosidine should be administered with caution to patients with ulcerative intestinal lesions to avoid renal toxicity through inadvertent absorption of the drug. High doses or prolonged therapy with Aminosidine should be avoided. Since Aminosidine is only active against intestinal protozoa, the drug should not be used in the treatment of extra-intestinal amoebiasis. Aminosidine is contraindicated in patients with intestinal obstruction and in patients with a known hypersensitivity to the drug.